About AVT
Browse Articles
Customer Services

Case report

Tenofovir alafenamide as part of a salvage regimen in a patient with multi-drug resistant HIV and tenofovir-DF-associated renal tubulopathy

James M Mikula, Maura M Manion, Frank Maldarelli, Lucila M Suarez, Jaha F Norman-Wheeler, Alex G Ober, Robin L Dewar, Jeffrey B Kopp, H Clifford Lane, Alice K Pau

Corresponding author name: Alice K Pau
Corresponding author e-mail: apau@niaid.nih.gov

Citation: Antiviral Therapy 2016; 21:553-558
doi: 10.3851/IMP3040

Date accepted: 20 February 2016
Date published online: 08 March 2016


We describe a patient with two recent episodes of tenofovir disoproxil fumarate (TDF)-associated acute kidney injury and six-class drug-resistant HIV infection who achieved and maintained viral suppression without worsening kidney function on a regimen including tenofovir alafenamide (TAF) through 48 weeks of therapy. The safety and efficacy of TAF in patients with TDF-associated renal tubulopathy and multiple drug resistant HIV has not yet been described. TAF may represent a useful option to maximally suppress HIV in patients with these complications.


Copyright © 2020 Nucleus Holdings Ltd. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.